Document



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2016
 
 
Cardiovascular Systems, Inc.
(Exact name of Registrant as Specified in its Charter)
 
 
 
 
 
 
 
 
Delaware
 
000-52082
 
41-1698056
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
1225 Old Highway 8 Northwest
St. Paul, Minnesota 55112-6416
(Address of Principal Executive Offices and Zip Code)
(651) 259-1600
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its 2016 Annual Meeting of Stockholders on November 16, 2016. Set forth below is a brief description of each matter voted upon at the meeting and the voting results with respect to each matter.

1.
Proposal to elect Class II directors to hold office until the fiscal 2019 Annual Meeting of Stockholders:
Class I Director's Name
 
For
 
Against
 
Abstain
 
Broker Non-Votes
Brent G. Blackey
 
21,987,597
 
212,582
 
23,075
 
5,169,910
Leslie L. Trigg
 
21,882,642
 
337,548
 
3,064
 
5,169,910
Scott R. Ward
 
21,914,873
 
293,446
 
14,935
 
5,169,910

2.
Proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending June 30, 2017.
For
 
Against
 
Abstain
27,347,058
 
37,636
 
8,470

3.
Proposal to cast a non-binding advisory vote on the compensation paid to the Company's named executive officers.
For
 
Against
 
Abstain
 
Broker Non-Votes
21,143,412
 
917,185
 
162,657
 
5,169,910








SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 18, 2016
 
 
 
 
CARDIOVASCULAR SYSTEMS, INC.
 
By:
 
/s/ Laurence L. Betterley
 
 
Laurence L. Betterley
Chief Financial Officer